Infectious Disease Research Institute, Seattle, WA 98104, USA.
Vaccine. 2009 Nov 23;27(50):7036-45. doi: 10.1016/j.vaccine.2009.09.066. Epub 2009 Sep 26.
Development of a protective subunit vaccine against Leishmania spp. depends on antigens and adjuvants that induce appropriate immune responses. We evaluated a second generation polyprotein antigen (Leish-110f) in different adjuvant formulations for immunogenicity and protective efficacy against Leishmania spp. challenges. Vaccine-induced protection was associated with antibody and T cell responses to Leish-110f. CD4 T cells were the source of IFN-gamma, TNF, and IL-2 double- and triple-positive populations. This study establishes the immunogenicity and protective efficacy of the improved Leish-110f subunit vaccine antigen adjuvanted with natural (MPL-SE) or synthetic (EM005) Toll-like receptor 4 agonists.
针对利什曼原虫的保护性亚单位疫苗的开发依赖于能够诱导适当免疫反应的抗原和佐剂。我们评估了第二代多蛋白抗原（Leish-110f）在不同佐剂配方中的免疫原性和针对利什曼原虫挑战的保护效果。疫苗诱导的保护与针对 Leish-110f 的抗体和 T 细胞反应相关。CD4 T 细胞是 IFN-γ、TNF 和 IL-2 双阳性和三阳性群体的来源。本研究确立了经天然（MPL-SE）或合成（EM005）Toll 样受体 4 激动剂佐剂增强的 Leish-110f 亚单位疫苗抗原的免疫原性和保护效力。
